HighTower Advisors’s Standard BioTools LAB Stock Holding History
Bought
Maintained
Sold
Other funds holding LAB
CC
MCO
LFCM
VCM
HBWM
HighTower Advisors's LAB Position: Q1 2026 in Review
HighTower Advisors increased its Standard BioTools (LAB) stake by 3.2% in Q1 2026, buying an estimated $2.06K and bringing the position to 54,491 shares worth $50.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3707.
HighTower Advisors first reported a position in LAB in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.94M in Q1 2023. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.
- HighTower Advisors held 54,491 shares of Standard BioTools worth $50.1K as of Q1 2026.
- HighTower Advisors bought 1,700 Standard BioTools shares in Q1 2026, an estimated $2.06K.
- Standard BioTools made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3707 holding.
- HighTower Advisors first reported a position in Standard BioTools in Q4 2021 and has held it in 18 quarters since.
- HighTower Advisors's Standard BioTools position peaked at $1.94M in Q1 2023.
- 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.
Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.